|Description||Acalisib, also known as GS-9820, is an inhibitor of the beta and delta isoforms of the 110 kDa catalytic subunit of class IA phosphoinositide-3 kinases (PI3K) with potential immunomodulating and antineoplastic activities. p110beta/delta PI3K inhibitor GS-9820 inhibits the activity of PI3K, thereby preventing the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), which decreases tumor cell proliferation and induces cell death. PI3K-mediated signaling is often dysregulated in cancer cells; the targeted inhibition of PI3K is designed to preserve PI3K signaling in normal, non-neoplastic cells.|
|Synonyms||GS-9820; GS9820; GS 9820; CAL-120; CAL 120; CAL120; Acalisib; UNII-OVW60IDW1D.|
|Current Developer||Gilead Sciences|
PIK-90 is a potent PI3K inhibitor.
GSK-2269557 HCl salt
GSK-2269557 is a selective Phosphatidylinositol 3 kinase delta inhibitor originated by GlaxoSmithKline. GSK-2269557 is highly selective for PI3Kδ over the close...
GDC-0084, a PI3K inhibitor, has been found to have probable antineoplastic effect and could pass blood-brain barrier with favourable penetration. It was just li...
PI3k(delta) inhibitor 1
PI3kδ inhibitor 1 is a potent and selective inhibitor of isoform of PI3Kδ; useful for treating disorders mediated by lipid kinases such as inflammation, immunol...
MLN1117, also known as INK1117, is a PI3Kα inhibitor which could lead to the apoptosis and growth retardation of tumor cells expressed by PI3Kα. IC50: 15 nM.
Desmethyl-VS-5584, a demethyl analogue of VS-5584, is a PI3K/mTOR kinase inhibitor for the treatment of cancer.
Pilaralisib, also known as XL147, is a methylbenzenesulfonamide derivative that reversibly inhibits class I PI3Ks (IC50s = 39, 36, 23, and 383 nM for p110α, δ, ...
PF-4989216 is a novel potent and selective PI3K inhibitor. PF-4989216 inhibits the phosphorylation of PI3K downstream molecules and subsequently leads to inhib...
Duvelisib R enantiomer
The R isomer analogue of Duvelisib which is a high selective PI3K δ/γ inhibitor.
Copanlisib, also known as BAY 80-6946, is a phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. BAY 80-6946 inhibits the activat...
LY3023414, a quinoline derivative, has been found to be a PI3Kα and mTOR inhibitor that could influence cell proliferation and cycle of tumor cells. It was just...
VPS34-IN1 is a potent and selective Vps34 inhibitor with potential anticancer activity. VPS34-IN1 inhibits Vps34 with 25 nM IC50 in vitro.
PIK-294 is a potent PI3K inhibitor.
BKM120, also called as buparlisib or NVP-BKM120, activity in a range of preclinical cancermodels, specifically inhbits class I PI3K isoforms, which blocks p110α...
CAL-130 racemate is a novel phosphoinositide 3-kinase (PI3K) inhibitor. It is reported that combined inhibition of PI3Kγ/δ as therapy for T cell acute lymphobla...
CNX-1351 is a selective covalent Inhibitor of PI3Kα. In an end point assay, CNX-1351 potently inhibited PI3Kα and was 20−400 times less potent against β, γ, an...
GSK2269557, an effective PI3K inhibitor, could be used as against inflammatory and some autoimmune diseases. It has just completes a phase II trial against Asth...
1,3-Dicaffeoylquinic acid, a caffeoylquinic acid derivative found in artichoke, acts as an anti-hyperlipidemic agent and activates PI3K/Akt.